Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,979,230
  • Shares Outstanding, K 149,284
  • Annual Sales, $ 8,250 K
  • Annual Income, $ -448,720 K
  • 60-Month Beta 0.77
  • Price/Sales 984.13
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BBIO with:

Options Overview

Details
  • Implied Volatility 54.89%
  • Historical Volatility 46.87%
  • IV Percentile 28%
  • IV Rank 22.74%
  • IV High 86.68% on 02/17/21
  • IV Low 45.53% on 12/10/20
  • Put/Call Vol Ratio 0.14
  • Today's Volume 16
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 3.10
  • Today's Open Interest 14,055
  • Open Int (30-Day) 13,974

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.93
  • Number of Estimates 6
  • High Estimate -0.34
  • Low Estimate -1.32
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +9.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.95 +0.94%
on 07/30/21
65.33 -18.18%
on 07/07/21
-7.51 (-12.32%)
since 06/30/21
3-Month
44.94 +18.94%
on 05/11/21
65.33 -18.18%
on 07/07/21
-2.47 (-4.42%)
since 04/30/21
52-Week
26.17 +104.24%
on 08/04/20
73.50 -27.28%
on 02/09/21
+23.74 (+79.91%)
since 07/30/20

Most Recent Stories

More News
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 53.45 (-1.71%)
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically...

FSNN : 0.0580 (-19.44%)
BMEA : 13.19 (-2.30%)
EIDX : 122.21 (-4.85%)
BBIO : 53.45 (-1.71%)
IOVA : 22.27 (-1.11%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ(TM) (infigratinib) for Patients with Cholangiocarcinoma

BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved TRUSELTIQ(TM) (infigratinib)...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ(TM) (infigratinib) for Patients with Cholangiocarcinoma

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021, the compensation committee of BridgeBio's board of directors...

BBIO : 53.45 (-1.71%)
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...

BBIO : 53.45 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 55.38
2nd Resistance Point 54.80
1st Resistance Point 54.12
Last Price 53.45
1st Support Level 52.86
2nd Support Level 52.28
3rd Support Level 51.60

See More

52-Week High 73.50
Fibonacci 61.8% 55.42
Last Price 53.45
Fibonacci 50% 49.83
Fibonacci 38.2% 44.25
52-Week Low 26.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar